Bocker W. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol. 2002;86:116–9.
CAS
PubMed
Google Scholar
Fletcher CD. The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification. Histopathology. 2014;64(1):2–11.
Article
Google Scholar
Bodner K, Bodner-Adler B, Obermair A, Windbichler G, Petru E, Mayerhofer S, Czerwenka K, Leodolter S, Kainz C, Mayerhofer K. Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol. 2001;81(2):160–5.
Article
CAS
Google Scholar
Feng W, Malpica A, Robboy SJ, Gudlaugsson E, Hua K, Zhou X, Baak JP. Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family. Int J Gynecol Pathol. 2013;32(3):299–306.
Article
Google Scholar
Lusby K, Savannah KB, Demicco EG, Zhang Y, Ghadimi MP, Young ED, Colombo C, Lam R, Dogan TE, Hornick JL, et al. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol. 2013;20(7):2364–72.
Article
Google Scholar
Coindre JM, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, Mandard AM, Vilain MO, Jacquemier J, Duplay H, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14(3):869–77.
Article
CAS
Google Scholar
Pautier P, Genestie C, Rey A, Morice P, Roche B, Lhomme C, Haie-Meder C, Duvillard P. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer. 2000;88(6):1425–31.
Article
CAS
Google Scholar
Hanley KZ, Birdsong GG, Mosunjac MB. Recent developments in surgical pathology of the uterine corpus. Arch Pathol Lab Med. 2017;141(4):528–41.
Article
Google Scholar
Sandberg AA. Cytogenetics and molecular genetics of bone and soft-tissue tumors. Am J Med Genet. 2002;115(3):189–93.
Article
Google Scholar
Cui RR, Wright JD, Hou JY. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome. BJOG. 2017;124(7):1028–37.
Article
CAS
Google Scholar
Lee CH, Ou WB, Marino-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A. 2012;109(3):929–34.
Article
CAS
Google Scholar
Lewis N, Soslow RA, Delair DF, Park KJ, Murali R, Hollmann TJ, Davidson B, Micci F, Panagopoulos I, Hoang LN, et al. ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Mod Pathol. 2017.
Micci F, Gorunova L, Agostini A, Johannessen LE, Brunetti M, Davidson B, Heim S, Panagopoulos I. Cytogenetic and molecular profile of endometrial stromal sarcoma. Genes Chromosomes Cancer. 2016;55(11):834–46.
Article
CAS
Google Scholar
Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 2016;122(19):2952–60.
Article
Google Scholar
Group ESESNW. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii102–12.
Article
Google Scholar
Mancari R, Signorelli M, Gadducci A, Carinelli S, De Ponti E, Sesana S, Corso S, Chiappa V, Colombo N, Lissoni AA. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients. Gynecol Oncol. 2014;133(3):531–6.
Article
CAS
Google Scholar
Bogani G, Fuca G, Maltese G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Scaffa C, Sabatucci I, Lecce F, et al. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol. 2016;143(2):443–7.
Article
CAS
Google Scholar
Ducie JA, Leitao MM, Jr.: The role of adjuvant therapy in uterine leiomyosarcoma. Expert Rev Anticancer Ther 2016, 16(1):45–55.
Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, et al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian sarcoma group and the Spanish sarcoma group. Ann Oncol. 2016;27(12):2283–8.
Article
CAS
Google Scholar
Roque DR, Taylor KN, Palisoul M, Wysham WZ, Milam B, Robison K, Gehrig PA, Raker C, Kim KH. Gemcitabine and docetaxel compared with observation, radiation, or other chemotherapy regimens as adjuvant treatment for stage I-to-IV uterine Leiomyosarcoma. Int J Gynecol Cancer. 2016;26(3):505–11.
Article
Google Scholar
Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397–410.
Article
CAS
Google Scholar
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, et al. Uterine sarcoma, version 1.2016: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2015;13(11):1321–31.
Article
Google Scholar
Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629–37.
Article
CAS
Google Scholar
Benson C, Ray-Coquard I, Sleijfer S, Litiere S, Blay JY, Le Cesne A, Papai Z, Judson I, Schoffski P, Chawla S, et al. Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group (STBSG) clinical trials 62043 and 62072. Gynecol Oncol. 2016;142(1):89–94.
Article
CAS
Google Scholar
Angarita FA, Cannell AJ, Abdul Razak AR, Dickson BC, Blackstein ME. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study. BMC Cancer. 2016;16:30.
Article
Google Scholar
Littell RD, Tucker LY, Raine-Bennett T, Palen TE, Zaritsky E, Neugebauer R, Embry-Schubert J, Lentz SE. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: trends and survival outcomes. Gynecol Oncol. 2017;147(1):11–7.
Article
CAS
Google Scholar
Benson C, Miah AB. Uterine sarcoma - current perspectives. Int J Womens Health. 2017;9:597–606.
Article
Google Scholar
Gremel G, Liew M, Hamzei F, Hardell E, Selling J, Ghaderi M, Stemme S, Ponten F, Carlson JW. A prognosis based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22 translocation status as predictors of survival. Int J Cancer. 2015;136(7):1608–18.
Article
CAS
Google Scholar
Bacalbasa N, Balescu I, Dima S, Brasoveanu V, Popescu I. Prognostic factors and survival in patients treated surgically for primary and recurrent uterine leiomyosarcoma: a single center experience. Anticancer Res. 2015;35(4):2229–34.
PubMed
Google Scholar
Hardell E, Josefson S, Ghaderi M, Skeie-Jensen T, Westbom-Fremer S, Cheek EH, Bell D, Selling J, Schoolmeester JK, Masback A, et al. Validation of a mitotic index cutoff as a prognostic marker in undifferentiated uterine sarcomas. Am J Surg Pathol. 2017;41(9):1231–7.
Article
Google Scholar
Andreou D, Werner M, Pink D, Traub F, Schuler M, Gosheger G, Jobke B, Reichardt P, Tunn PU. Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma. Br J Cancer. 2015;112(3):455–60.
Article
CAS
Google Scholar
Lee C-H, Mariño-Enriquez A, Ou W, Zhu M, Ali RH, Chiang S, Amant F, Gilks CB, van de Rijn M, Oliva E, et al. The Clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol. 2012;36(5):641–53.
Article
Google Scholar
Ravid Y, Formanski M, Smith Y, Reich R, Davidson B. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures. Gynecol Oncol. 2016;140(3):512–7.
Article
Google Scholar
Davidson B, Micci F. Molecular characteristics of uterine sarcomas. Expert Rev Mol Diagn. 2017;17(5):515–22.
Article
CAS
Google Scholar
Lee CH, Ali RH, Rouzbahman M, Marino-Enriquez A, Zhu M, Guo X, Brunner AL, Chiang S, Leung S, Nelnyk N, et al. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 2012;36(10):1562–70.
Article
Google Scholar
Feng W, Malpica A, Skaland I, Gudlaugsson E, Robboy SJ, Dalen I, Hua K, Zhou X, Baak JP. Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade? PLoS One. 2013;8(10):e75899.
Article
CAS
Google Scholar